High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy

Area of Science:

• Oncology
• Immunology
• Cancer Therapeutics

Background:

• Neuroblastoma (NB) is a heterogeneous cancer of the sympathetic nervous system with approximately 50% cure rates despite intensive treatment.
• Relapsed or refractory high-risk neuroblastoma (HRNB) presents significant therapeutic challenges.
• Risk stratification and stage-adapted therapies have improved outcomes but curative challenges persist.

Purpose of the Study:

• To review current immune approaches for neuroblastoma (NB).
• To discuss the tumor microenvironment (TME) in the context of NB immunotherapy.
• To propose a novel T cell-based therapeutic strategy for HRNB.

Main Methods:

• Review of existing literature on immunotherapy for neuroblastoma.
• Analysis of immune strategies including monoclonal antibodies, vaccines, and adoptive cell therapy.
• Exploration of the tumor microenvironment (TME) and its role in NB pathogenesis and treatment.

Main Results:

• Immunotherapy, including targeted agents like monoclonal antibodies, is an attractive option for relapsed/refractory HRNB.
• Adoptive cellular therapies and their combinations show potential but face toxicity concerns.
• Leveraging tumor surface antigens like ganglioside GD2 is a key strategy.

Conclusions:

• Novel T cell-based immunotherapies hold promise for improving cure rates in high-risk neuroblastoma.
• Integrating advancements in adoptive cell therapy with antibody-based approaches may overcome current limitations.
• Further research into TME modulation is crucial for optimizing NB immunotherapy.